Yao Cheng2020-03-18T10:37:26+01:00March 18th, 2020|
Redbiotec AG has entered into a research collaboration and exclusive option agreement with a large-cap pharmaceutical company. The collaboration will leverage Redbiotec’s proprietary bacteria platform BRISPR® for the targeted delivery of gene therapy cargos from the partner.
“Redbiotec’s bacteria hold great potential in overcoming the delivery hurdles faced by conventional vehicles, such as adeno-associated viruses (AAVs) and nanoparticles. It is our goal to empower promising gene therapies for unmet medical needs through safe and targeted delivery,” said Christian Schaub, CEO of Redbiotec. “We are very pleased with our first pharma partnership on the BRISPR® platform. Together, we will push the boundaries and create a new class of genetic medicines.”
Redbiotec AG, a pioneer in living medicines, further expands its Scientific Advisory Board with the appointment of Professor Michele Calos, PhD. Dr. Calos is a Professor of Genetics at Stanford University. A recent President of the American Society of Gene and Cell Therapy (ASGCT), Dr. Calos brings over four decades of research experience in genetics and genomic modification and has been focused on developing novel gene and cell therapies to improve the clinical condition of patients suffering from genetic disorders like muscular dystrophy. Dr. Calos has also served on the Advisory Committee to the FDA with regard to cell, tissue and gene therapies. Dr. Calos is an Oxford graduate and received her PhD in Biochemistry & Molecular Biology from Harvard University.
As Redbiotec enters the field of gene therapy with engineered bacteria as means to improve in vivo delivery of therapeutics, we greatly appreciate the research experience and regulatory insights brought by Dr. Calos.